Dr. Page is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4805 NE Glisan St
Portland, OR 97213Phone+1 503-215-1350Fax+1 503-215-5695- Is this information wrong?
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2015
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
Northwestern University The Feinberg School of MedicineClass of 2009
Certifications & Licensure
OR State Medical License 2015 - 2025
NY State Medical License 2011 - 2016- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Start of enrollment: 2019 Apr 03
- Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer Start of enrollment: 2021 Sep 10
Publications & Presentations
PubMed
- Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer.Elizabeth Comen, Sadna Budhu, Yuval Elhanati, David Page, Teresa Rasalan-Ho, Erika Ritter, Phillip Wong, George Plitas, Sujata Patil, Edi Brogi, Maxine Jochelson, Yola...> ;Iscience. 2024 Feb 16
- Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast C...Chowdhury Arif Jahangir, David B Page, Glenn Broeckx, Claudia A Gonzalez, Caoimbhe Burke, Clodagh Murphy, Jorge S Reis-Filho, Amy Ly, Paul W Harms, Rajarsi R Gupta, Mi...> ;The Journal of Pathology. 2024 Mar 1
- 6 citationsPitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group...Jeppe Thagaard, Glenn Broeckx, David B Page, Chowdhury Arif Jahangir, Sara Verbandt, Zuzana Kos, Rajarsi Gupta, Reena Khiroya, Khalid Abduljabbar, Gabriela Acosta Haab...> ;The Journal of Pathology. 2023 Aug 1
- Join now to see all
Lectures
- A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metast...2019 ASCO Annual Meeting - 6/1/2019
- Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast CancerFebruary 25th, 2021- NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)November 7th, 2018
IRX Therapeutics Announces Presentation of IRX-2 Phase 1b Biomarker Data in Early Stage Breast CancerNovember 10th, 2017- Join now to see all
Hospital Affiliations
Providence Hood River Memorial HospitalHood River, Oregon
Providence Milwaukie HospitalPortland, Oregon
Providence Newberg Medical CenterNewberg, Oregon
Providence Portland Medical CenterPortland, Oregon
Providence Seaside HospitalSeaside, Oregon
Providence St. Vincent Medical CenterPortland, Oregon
Providence Willamette Falls Medical CenterOregon City, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
